

# Mario M Leitao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7572737/publications.pdf>

Version: 2024-02-01

172  
papers

7,307  
citations

50276

46  
h-index

64796

79  
g-index

173  
all docs

173  
docs citations

173  
times ranked

5968  
citing authors

#	ARTICLE	IF	CITATIONS
1	Open vs minimally invasive radical trachelectomy in early-stage cervical cancer: International Radical Trachelectomy Assessment Study. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 97.e1-97.e16.	1.3	20
2	Factors Associated With Premature Ovarian Insufficiency in Young Women With Locally Advanced Rectal Cancer Treated With Pelvic Radiation Therapy. <i>Advances in Radiation Oncology</i> , 2022, 7, 100801.	1.2	6
3	Clear cell carcinoma of the endometrium. <i>Gynecologic Oncology</i> , 2022, 164, 658-666.	1.4	23
4	Risk factors for postoperative wound dehiscence after skin repair: A case-control study. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 1099-1102.	1.2	1
5	Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease. <i>JAMA Oncology</i> , 2022, 8, 618.	7.1	46
6	Radical Hysterectomy for Cervical Cancer: the Right Surgical Approach. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1-14.	3.0	6
7	Sentinel lymph node biopsy alone compared to systematic lymphadenectomy in patients with uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2022, 165, 287-292.	1.4	9
8	Gynecologic Survivorship Tool: Development, Implementation, and Symptom Outcomes. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100154.	2.1	2
9	The end of routine lymphadenectomy for the treatment of cervical cancer is rapidly approaching. <i>Gynecologic Oncology</i> , 2022, 164, 461-462.	1.4	0
10	Risk factors for financial toxicity in patients with gynecologic cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 817.e1-817.e9.	1.3	20
11	Primary characteristics and outcomes of newly diagnosed low-grade endometrial stromal sarcoma. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 882-890.	2.5	4
12	Urethral Melanoma – Clinical, Pathological and Molecular Characteristics. <i>Bladder Cancer</i> , 2022, 8, 291-301.	0.4	1
13	Targeted RNA expression profiling identifies high-grade endometrial stromal sarcoma as a clinically relevant molecular subtype of uterine sarcoma. <i>Modern Pathology</i> , 2021, 34, 1008-1016.	5.5	27
14	The impact of tumor fragmentation in patients with stage I uterine leiomyosarcoma on patterns of recurrence and oncologic outcome. <i>Gynecologic Oncology</i> , 2021, 160, 99-105.	1.4	10
15	The Landmark Series: Minimally Invasive Surgery for Cervical Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 204-211.	1.5	8
16	Prophylactic Negative Pressure Wound Therapy After Laparotomy for Gynecologic Surgery. <i>Obstetrics and Gynecology</i> , 2021, 137, 334-341.	2.4	12
17	Treatment of Extramammary Paget Disease and the Role of Reflectance Confocal Microscopy: A Prospective Study. <i>Dermatologic Surgery</i> , 2021, 47, 473-479.	0.8	8
18	Monitoring vulvar melanoma response to combined immunotherapy and radiotherapy with <i>in vivo</i> reflectance confocal microscopy. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 768-770.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Global disparities in oncology: Pinpointing and addressing the causes. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 153, 188-189.	2.3	0
20	Development of a surgical competency assessment tool for sentinel lymph node dissection by minimally invasive surgery for endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 647-655.	2.5	28
21	Multiparametric magnetic resonance imaging facilitates the selection of patients prior to fertility-sparing management of endometrial cancer. <i>Abdominal Radiology</i> , 2021, 46, 4410-4419.	2.1	4
22	Immediate lymphatic reconstruction: the time is right to prevent lymphedema following lymphadenectomy for vulvar cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 943-943.	2.5	2
23	Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer. <i>Gynecologic Oncology</i> , 2021, 161, 535-544.	1.4	16
24	Uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2021, 162, 226-234.	1.4	58
25	Clinical outcomes of patients with endometrioid epithelial ovarian cancer following surgical treatment. <i>Journal of Surgical Oncology</i> , 2021, 124, 846-851.	1.7	0
26	Sentinel lymph node biopsy in patients with endometrial cancer and an indocyanine green or iodinated contrast reaction - A proposed management algorithm. <i>Gynecologic Oncology</i> , 2021, 162, 262-267.	1.4	12
27	Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II. <i>Journal of Clinical Oncology</i> , 2021, 39, 3623-3632.	1.6	69
28	Non-exenterative surgical management of recurrent endometrial carcinoma. <i>Gynecologic Oncology</i> , 2021, 162, 268-276.	1.4	5
29	Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis. <i>Gynecologic Oncology</i> , 2021, 162, 345-352.	1.4	8
30	Pattern of disease and response to pembrolizumab in recurrent cervical cancer. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100831.	0.6	4
31	Quaternary and beyond cytoreduction: An updated and expanded analysis. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100851.	0.6	1
32	Pelvic exenteration for recurrent or persistent gynecologic malignancies: Clinical and histopathologic factors predicting recurrence and survival in a modern cohort. <i>Gynecologic Oncology</i> , 2021, 163, 294-298.	1.4	9
33	Post-LACC era: critical assessment not "all-or-none" is needed. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e47.	2.2	3
34	Surgical ovarian suppression for adjuvant treatment in hormone receptor positive breast cancer in premenopausal patients. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 222-231.	2.5	2
35	Metastatic melanoma concurrent to the urinary bladder and endometrium: Case report. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2021, , .	1.8	1
36	Minimally invasive surgery versus laparotomy for radical hysterectomy in the management of early-stage cervical cancer: Survival outcomes. <i>Gynecologic Oncology</i> , 2020, 156, 591-597.	1.4	54

#	ARTICLE	IF	CITATIONS
37	Lower extremity lymphedema in patients with gynecologic malignancies. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 252-260.	2.5	53
38	The aftershocks of the LACC earthquake have begun: brace yourselves. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 157-159.	2.5	2
39	Sentinel lymph node mapping alone compared to more extensive lymphadenectomy in patients with uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2020, 156, 70-76.	1.4	37
40	Multicenter study comparing oncologic outcomes after lymph node assessment via a sentinel lymph node algorithm versus comprehensive pelvic and paraaortic lymphadenectomy in patients with serous and clear cell endometrial carcinoma. <i>Gynecologic Oncology</i> , 2020, 156, 62-69.	1.4	43
41	Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer. <i>Gynecologic Oncology</i> , 2020, 156, 194-202.	1.4	35
42	Patient-reported outcomes after surgery for endometrial carcinoma: Prevalence of lower-extremity lymphedema after sentinel lymph node mapping versus lymphadenectomy. <i>Gynecologic Oncology</i> , 2020, 156, 147-153.	1.4	61
43	Machine learning-based prediction of microsatellite instability and high tumor mutation burden from contrast-enhanced computed tomography in endometrial cancers. <i>Scientific Reports</i> , 2020, 10, 17769.	3.3	35
44	Genomic Alterations as Potential Therapeutic Targets in Extramammary Paget's Disease of the Vulva. <i>JCO Precision Oncology</i> , 2020, 4, 1054-1060.	3.0	12
45	Comparison of minimally invasive versus open surgery in the treatment of endometrial carcinosarcoma. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1162-1168.	2.5	6
46	Electronic patient-reported symptom monitoring in patients recovering from ambulatory minimally invasive gynecologic surgery: A prospective pilot study. <i>Gynecologic Oncology</i> , 2020, 159, 187-194.	1.4	12
47	Radical Trachelectomy for the Treatment of Early-Stage Cervical Cancer. <i>Obstetrics and Gynecology</i> , 2020, 136, 533-542.	2.4	61
48	ASO Author Reflections: Robotically Assisted Gynecologic Surgery in the Frail Elderly: Analysis of Perioperative Outcomes. <i>Annals of Surgical Oncology</i> , 2020, 27, 3781-3782.	1.5	0
49	Update on Sentinel Lymph Node Mapping in Endometrial Cancer Patients with a High Risk for Nodal Metastasis. <i>Indian Journal of Gynecologic Oncology</i> , 2020, 18, 1.	0.3	3
50	The current clinical approach to newly diagnosed uterine cancer. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 581-590.	2.4	3
51	Surveillance patterns of cervical cancer patients treated with conization alone. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1129-1135.	2.5	3
52	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. <i>PLoS ONE</i> , 2020, 15, e0234505.	2.5	25
53	Current and novel mapping substances in gynecologic cancer care. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 387-393.	2.5	9
54	When to Operate, Hesitate and Reintegrate: Society of Gynecologic Oncology Surgical Considerations during the COVID-19 Pandemic. <i>Gynecologic Oncology</i> , 2020, 158, 236-243.	1.4	42

#	ARTICLE	IF	CITATIONS
55	The impact of near-infrared angiography and proctoscopy after rectosigmoid resection and anastomosis performed during surgeries for gynecologic malignancies. <i>Gynecologic Oncology</i> , 2020, 158, 397-401.	1.4	7
56	Impact of hospital volume on surgical management and outcomes for early-stage cervical cancer. <i>Gynecologic Oncology</i> , 2020, 157, 508-513.	1.4	11
57	Incidence of pelvic lymph node metastasis using modern FIGO staging and sentinel lymph node mapping with ultrastaging in surgically staged patients with endometrioid and serous endometrial carcinoma. <i>Gynecologic Oncology</i> , 2020, 157, 619-623.	1.4	32
58	Robotic Surgery in the Frail Elderly: Analysis of Perioperative Outcomes. <i>Annals of Surgical Oncology</i> , 2020, 27, 3772-3780.	1.5	16
59	Impact of provider volume on front-line chemotherapy guideline compliance and overall survival in elderly patients with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 159, 418-425.	1.4	7
60	Asian Society for Gynecologic Robotic Surgery consensus guidelines on robotic surgery in gynecological cancer. <i>Gynecologic Robotic Surgery</i> , 2020, 1, 2-13.	0.2	2
61	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. , 2020, 15, e0234505.		0
62	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. , 2020, 15, e0234505.		0
63	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. , 2020, 15, e0234505.		0
64	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. , 2020, 15, e0234505.		0
65	Impact of Sentinel Node Approach in Gynecologic Cancer on Training Needs. <i>Journal of Minimally Invasive Gynecology</i> , 2019, 26, 727-732.	0.6	6
66	Molecular profiling and molecular classification of endometrioid ovarian carcinomas. <i>Gynecologic Oncology</i> , 2019, 154, 516-523.	1.4	62
67	Role of lymphadenectomy in endometrial cancer with nonbulky lymph node metastasis: Comparison of comprehensive surgical staging and sentinel lymph node algorithm. <i>Gynecologic Oncology</i> , 2019, 155, 177-185.	1.4	38
68	Factors influencing the adoption of the sentinel lymph node technique for endometrial cancer staging: an international survey of gynecologic oncologists. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 60-67.	2.5	43
69	Secondary surgical resection for patients with recurrent uterine leiomyosarcoma. <i>Gynecologic Oncology</i> , 2019, 154, 333-337.	1.4	14
70	Vulvar melanoma: management of primary disease and repeated recurrences. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1077-1081.	2.5	3
71	Ultrastaging of negative pelvic lymph nodes to decrease the true prevalence of isolated paraaortic dissemination in endometrial cancer. <i>Gynecologic Oncology</i> , 2019, 154, 60-64.	1.4	35
72	Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status. <i>Gynecologic Oncology</i> , 2019, 154, 144-149.	1.4	24

#	ARTICLE	IF	CITATIONS
73	The change in landscape after a new landmark is constructed: Radical hysterectomy for early cervical cancer and Minimally Invasive Surgery. <i>Gynecologic Oncology</i> , 2019, 153, 1-2.	1.4	14
74	Robotic-assisted psoas hitch with ureteral reimplantation. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 223-223.	2.5	0
75	SENTICOL III: an international validation study of sentinel node biopsy in early cervical cancer. A GINECO, ENGOT, GCIG and multicenter study. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 829-834.	2.5	102
76	International radical trachelectomy assessment: IRTA study. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 635-638.	2.5	35
77	Understanding Inherited Risk in Unselected Newly Diagnosed Patients With Endometrial Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-15.	3.0	7
78	Prognostic significance of supraclavicular lymphadenopathy in patients with high-grade serous ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1377-1380.	2.5	7
79	Risk-based stratification of carcinomas concurrently involving the endometrium and ovary. <i>Gynecologic Oncology</i> , 2019, 152, 38-45.	1.4	18
80	Is Robotic-Assisted Surgery Safe in the Elderly Population? An Analysis of Gynecologic Procedures in Patients ≥65 Years Old. <i>Annals of Surgical Oncology</i> , 2019, 26, 244-251.	1.5	18
81	Comparison of outcomes in early-stage uterine clear cell carcinoma and serous carcinoma. <i>Brachytherapy</i> , 2019, 18, 38-43.	0.5	8
82	Adjuvant chemotherapy in patients with operable granulosa cell tumors of the ovary: a surveillance, epidemiology, and end results cohort study. <i>Cancer Medicine</i> , 2018, 7, 2280-2287.	2.8	21
83	Minimally invasive hysterectomy surgery rates for endometrial cancer performed at National Comprehensive Cancer Network (NCCN) Centers. <i>Gynecologic Oncology</i> , 2018, 148, 480-484.	1.4	60
84	ZC3H7B-BCOR high-grade endometrial stromal sarcomas: a report of 17 cases of a newly defined entity. <i>Modern Pathology</i> , 2018, 31, 674-684.	5.5	130
85	Brain metastases in patients with low-grade endometrial carcinoma. <i>Gynecologic Oncology Reports</i> , 2018, 26, 87-90.	0.6	9
86	Patterns of FIRST recurrence of stage IIIC1 endometrial cancer with no PARAAORTIC nodal assessment. <i>Gynecologic Oncology</i> , 2018, 151, 395-400.	1.4	14
87	Radical Hysterectomy. , 2018, , 181-192.		0
88	Robotic Surgery. , 2018, , 364-380.		0
89	The LACC Trial: Has Minimally Invasive Surgery for Early-Stage Cervical Cancer Been Dealt a Knockout Punch?. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1248-1250.	2.5	31
90	Multicenter study comparing oncologic outcomes between two nodal assessment methods in patients with deeply invasive endometrioid endometrial carcinoma: A sentinel lymph node algorithm versus a comprehensive pelvic and paraaortic lymphadenectomy. <i>Gynecologic Oncology</i> , 2018, 151, 235-242.	1.4	63

#	ARTICLE	IF	CITATIONS
91	Less versus more radical surgery in stage IB1 cervical cancer: A population-based study of long-term survival. <i>Gynecologic Oncology</i> , 2018, 150, 44-49.	1.4	30
92	Robotic Para-aortic Lymph Node Dissection. , 2018, , 131-140.		0
93	Management of epithelial ovarian cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2018, 16, 656-659.	0.3	6
94	A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 145, 230-235.	1.4	43
95	Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?. <i>Gynecologic Oncology</i> , 2017, 145, 15-20.	1.4	55
96	Survival of Patients with Serous Uterine Carcinoma Undergoing Sentinel Lymph Node Mapping. <i>Annals of Surgical Oncology</i> , 2017, 24, 1965-1971.	1.5	47
97	A Comparison of the Detection of Sentinel Lymph Nodes Using Indocyanine Green and Near-Infrared Fluorescence Imaging Versus Blue Dye During Robotic Surgery in Uterine Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 743-747.	2.5	42
98	Minimal access surgery compared to laparotomy for secondary surgical cytoreduction in patients with recurrent ovarian carcinoma: Perioperative and oncologic outcomes. <i>Gynecologic Oncology</i> , 2017, 146, 263-267.	1.4	33
99	Comparison of a sentinel lymph node mapping algorithm and comprehensive lymphadenectomy in the detection of stage IIIC endometrial carcinoma at higher risk for nodal disease. <i>Gynecologic Oncology</i> , 2017, 147, 541-548.	1.4	82
100	Trocar site hernia development in patients undergoing robotically assisted or standard laparoscopic staging surgery for endometrial cancer. <i>Gynecologic Oncology</i> , 2017, 147, 371-374.	1.4	7
101	Surgical site infection reduction bundle in patients with gynecologic cancer undergoing colon surgery. <i>Gynecologic Oncology</i> , 2017, 147, 115-119.	1.4	31
102	Robotically Assisted Laparoscopic Ovarian Transposition in Women with Lower Gastrointestinal Cancer Undergoing Pelvic Radiotherapy. <i>Annals of Surgical Oncology</i> , 2017, 24, 251-256.	1.5	14
103	Does para-aortic irradiation reduce the risk of distant metastasis in advanced cervical cancer? A systematic review and meta-analysis of randomized clinical trials. <i>Gynecologic Oncology</i> , 2017, 144, 312-317.	1.4	31
104	Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With <i>BRCA</i> Mutations. <i>JAMA Oncology</i> , 2016, 2, 1434.	7.1	189
105	Sentinel Lymph Node Mapping in Patients with Endometrial Carcinoma: Less Can Be More. <i>Current Obstetrics and Gynecology Reports</i> , 2016, 5, 279-285.	0.8	16
106	Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tract. <i>Gynecologic Oncology Reports</i> , 2016, 16, 42-46.	0.6	40
107	Impact of Obesity on Sentinel Lymph Node Mapping in Patients with Newly Diagnosed Uterine Cancer Undergoing Robotic Surgery. <i>Annals of Surgical Oncology</i> , 2016, 23, 2522-2528.	1.5	69
108	A pilot study of topical imiquimod therapy for the treatment of recurrent extramammary Paget's disease. <i>Gynecologic Oncology</i> , 2016, 142, 139-143.	1.4	57



#	ARTICLE	IF	CITATIONS
109	Impact of Robotic Platforms on Surgical Approach and Costs in the Management of Morbidly Obese Patients with Newly Diagnosed Uterine Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 2192-2198.	1.5	43
110	The role of adjuvant therapy in uterine leiomyosarcoma. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 45-55.	2.4	22
111	Low-Volume Lymph Node Metastasis Discovered During Sentinel Lymph Node Mapping for Endometrial Carcinoma. <i>Annals of Surgical Oncology</i> , 2016, 23, 1653-1659.	1.5	114
112	Herniation formation in women undergoing robotically assisted laparoscopy or laparotomy for endometrial cancer. <i>Gynecologic Oncology</i> , 2016, 140, 383-386.	1.4	10
113	Comparison of a sentinel lymph node and a selective lymphadenectomy algorithm in patients with endometrioid endometrial carcinoma and limited myometrial invasion. <i>Gynecologic Oncology</i> , 2016, 140, 394-399.	1.4	139
114	Survival of Patients with Uterine Carcinosarcoma Undergoing Sentinel Lymph Node Mapping. <i>Annals of Surgical Oncology</i> , 2016, 23, 196-202.	1.5	86
115	Molecular Subtypes of Uterine Leiomyosarcoma and Correlation with Clinical Outcome. <i>Neoplasia</i> , 2015, 17, 183-189.	5.3	33
116	Ovarian clear cell carcinoma, outcomes by stage: The MSK experience. <i>Gynecologic Oncology</i> , 2015, 139, 236-241.	1.4	70
117	Improving Sentinel Lymph Node Detection in Patients with Cervical Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 4115-4116.	1.5	1
118	Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 138, 246-251.	1.4	71
119	Management of Vulvar and Vaginal Melanomas: Current and Future Strategies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e277-e281.	3.8	45
120	Histological features associated with occult lymph node metastasis in <scp>FIGO</scp> clinical stage <scp>I</scp>, grade <scp>I</scp> endometrioid carcinoma. <i>Histopathology</i> , 2014, 64, 389-398.	2.9	40
121	Gynecologic Cancer InterGroup (GFIG) Consensus Review for Vulvovaginal Melanomas. <i>International Journal of Gynecological Cancer</i> , 2014, 24, S117-S122.	2.5	67
122	Cost-Effectiveness Analysis of Robotically Assisted Laparoscopy for Newly Diagnosed Uterine Cancers. <i>Obstetrics and Gynecology</i> , 2014, 123, 1031-1037.	2.4	60
123	Detection of sentinel lymph nodes in minimally invasive surgery using indocyanine green and near-infrared fluorescence imaging for uterine and cervical malignancies. <i>Gynecologic Oncology</i> , 2014, 133, 274-277.	1.4	246
124	Venous thromboembolism and minimally invasive surgery in gynecologic oncology: Time to re-evaluate and refocus. <i>Gynecologic Oncology</i> , 2014, 134, 217-218.	1.4	5
125	Endometrial cancer: A review and current management strategies: Part II. <i>Gynecologic Oncology</i> , 2014, 134, 393-402.	1.4	305
126	A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. <i>Gynecologic Oncology</i> , 2014, 134, 455-461.	1.4	180



#	ARTICLE	IF	CITATIONS
127	The feasibility and safety of same-day discharge after robotic-assisted hysterectomy alone or with other procedures for benign and malignant indications. <i>Gynecologic Oncology</i> , 2014, 133, 552-555.	1.4	75
128	Fellowship learning curve associated with completing a robotic assisted total laparoscopic hysterectomy. <i>Gynecologic Oncology</i> , 2014, 132, 102-106.	1.4	40
129	Feasibility and perioperative outcomes of robotic-assisted surgery in the management of recurrent ovarian cancer: A multi-institutional study. <i>Gynecologic Oncology</i> , 2014, 134, 253-256.	1.4	41
130	Endometrial cancer: A review and current management strategies: Part I. <i>Gynecologic Oncology</i> , 2014, 134, 385-392.	1.4	339
131	Endometrial Cancer Prevention. , 2014, , 593-611.		1
132	Sentinel lymph node mapping with pathologic ultrastaging: A valuable tool for assessing nodal metastasis in low-grade endometrial cancer with superficial myoinvasion. <i>Gynecologic Oncology</i> , 2013, 131, 714-719.	1.4	76
133	Parenchymal splenic metastasis is an independent negative predictor of overall survival in advanced ovarian, fallopian tube, and primary peritoneal cancer. <i>Gynecologic Oncology</i> , 2013, 128, 28-33.	1.4	11
134	Classification and regression tree (CART) analysis of endometrial carcinoma: Seeing the forest for the trees. <i>Gynecologic Oncology</i> , 2013, 130, 452-456.	1.4	87
135	Postoperative Pain Medication Requirements in Patients Undergoing Computer-Assisted (â€œRoboticâ€) and Standard Laparoscopic Procedures for Newly Diagnosed Endometrial Cancer. <i>Annals of Surgical Oncology</i> , 2013, 20, 3561-3567.	1.5	48
136	Expanding the Indications for Radical Trachelectomy. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 1092-1098.	2.5	77
137	Improving safety in robotic surgery: Intraoperative crisis checklist. <i>Journal of Surgical Oncology</i> , 2013, 108, 139-140.	1.7	5
138	In Reply. <i>Obstetrics and Gynecology</i> , 2013, 121, 877.	2.4	0
139	Lymphatic Mapping and Sentinel Lymph Node Biopsy in Women With Squamous Cell Carcinoma of the Vulva: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 3786-3791.	1.6	317
140	Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma. <i>Gynecologic Oncology</i> , 2012, 124, 558-562.	1.4	73
141	Introduction of a computer-based surgical platform in the surgical care of patients with newly diagnosed uterine cancer: Outcomes and impact on approach. <i>Gynecologic Oncology</i> , 2012, 125, 394-399.	1.4	28
142	Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis. <i>Gynecologic Oncology</i> , 2012, 125, 409-413.	1.4	58
143	The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: Beyond removal of blue nodes. <i>Gynecologic Oncology</i> , 2012, 125, 531-535.	1.4	353
144	A nomogram to predict postresection 5â€year overall survival for patients with uterine leiomyosarcoma. <i>Cancer</i> , 2012, 118, 660-669.	4.1	126

#	ARTICLE	IF	CITATIONS
145	Clinical Approach to Diagnosis and Management of Endometrial Hyperplasia and Carcinoma. Surgical Pathology Clinics, 2011, 4, 113-130.	1.7	1
146	Ventral hernia following primary laparotomy for ovarian, fallopian tube, and primary peritoneal cancers. Gynecologic Oncology, 2011, 120, 33-37.	1.4	15
147	Advances in the management of endometrial carcinoma. Gynecologic Oncology, 2011, 120, 489-492.	1.4	18
148	Micropapillary Pattern in Newly Diagnosed Borderline Tumors of the Ovary: What's in a Name?. Oncologist, 2011, 16, 133-135.	3.7	2
149	Endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma with a background of complex atypical hyperplasia and final hysterectomy pathology. American Journal of Obstetrics and Gynecology, 2010, 202, 278.e1-278.e6.	1.3	12
150	Complex atypical hyperplasia of the uterus: characteristics and prediction of underlying carcinoma risk. American Journal of Obstetrics and Gynecology, 2010, 203, 349.e1-349.e6.	1.3	47
151	Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. Gynecologic Oncology, 2010, 116, 424-429.	1.4	92
152	Postoperative intra-abdominal collections using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier at the time of laparotomy for uterine or cervical cancers. Gynecologic Oncology, 2010, 119, 208-211.	1.4	6
153	Stage-Specific Outcomes of Patients With Uterine Leiomyosarcoma: A Comparison of the International Federation of Gynecology and Obstetrics and American Joint Committee on Cancer Staging Systems. Journal of Clinical Oncology, 2009, 27, 2066-2072.	1.6	119
154	A Prospective Outcomes Analysis of Palliative Procedures Performed for Malignant Intestinal Obstruction Due to Recurrent Ovarian Cancer. Oncologist, 2009, 14, 835-839.	3.7	56
155	Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma. Gynecologic Oncology, 2009, 113, 105-108.	1.4	121
156	The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes. Gynecologic Oncology, 2009, 115, 236-238.	1.4	164
157	Postoperative intra-abdominal collections using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier at the time of laparotomy for ovarian, fallopian tube, or primary peritoneal cancers. Gynecologic Oncology, 2009, 115, 204-208.	1.4	21
158	Surgical Management of Recurrent Ovarian Cancer. Seminars in Oncology, 2009, 36, 106-111.	2.2	55
159	Staging and Surgical Treatment. Cancer Treatment and Research, 2009, 149, 35-61.	0.5	0
160	Cervical cancer in patients infected with the human immunodeficiency virus. Cancer, 2008, 112, 2683-2689.	4.1	22
161	Accuracy of preoperative endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma. Gynecologic Oncology, 2008, 111, 244-248.	1.4	69
162	Current and future surgical approaches in the management of endometrial carcinoma. Future Oncology, 2008, 4, 389-401.	2.4	14

#	ARTICLE	IF	CITATIONS
163	Fertility-sparing surgery in gynecologic oncology. Expert Review of Obstetrics and Gynecology, 2008, 3, 211-221.	0.4	1
164	Operative management of primary epithelial ovarian cancer. Current Oncology Reports, 2007, 9, 478-484.	4.0	8
165	Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. Gynecologic Oncology, 2004, 93, 301-306.	1.4	76
166	Tertiary cytoreduction in patients with recurrent ovarian carcinoma. Gynecologic Oncology, 2004, 95, 181-188.	1.4	66
167	Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer, 2004, 101, 1455-1462.	4.1	152
168	Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. Gynecologic Oncology, 2003, 91, 123-129.	1.4	43
169	Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus. Gynecologic Oncology, 2003, 91, 209-212.	1.4	159
170	Preoperative CA-125 Levels in Patients with Hereditary Compared to Sporadic Epithelial Ovarian Carcinoma. Gynecologic Oncology, 2002, 84, 413-415.	1.4	4
171	Recurrent cervical cancer. Current Treatment Options in Oncology, 2002, 3, 105-111.	3.0	36
172	Surgical Resection of Pulmonary and Extrapulmonary Recurrences of Uterine Leiomyosarcoma. Gynecologic Oncology, 2002, 87, 287-294.	1.4	84